Updates on EBV vaccine trial, DMT costs, and Mavenclad in MS news.
EBViously plans to bring its candidate vaccine against the Epstein-Barr virus into clinical trials starting in 2024, which could reduce the incidence of MS. A study found that the costs of infusible DMTs, Ocrevus, Tysabri, and Lemtrada, accounted for more than three-quarters of the total costs, and controlling price markups for medications could help limit healthcare costs for patients. A real-world data study says the benefits of Mavenclad were sustained for up to 15 years after its last treatment course in people with relapsing MS. The FDA has put a partial hold on trials of evobrutinib in MS after two patients in Phase 3 clinical trials were found to have elevations in their liver enzymes.
